Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastoma

American Journal of Cancer Research

Volumn 6, Issue 3, 2016, Pages 639-648

  da Ros, Martina ^a   Iorio, Anna Lisa ^a   Consolante, Dario ^b   Cardile, Francesco ^b   Muratori, Monica ^c   Fantappiè, Ornella ^c   Lucchesi, Maurizio ^a   Guidi, Milena ^a   Pisano, Claudio ^b   Sardi, Iacopo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Grande Ospedale Metropolitano   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Blood brain barrier; Doxorubicin; Glioblastoma; Morphine; P glycoprotein

Indexed keywords

DOXORUBICIN; MORPHINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BIOLUMINESCENCE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MORTALITY RATE; MOUSE; NONHUMAN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84992310707     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007; 6: 1909-1919.
2. Chastagner P, Devictor B, Geoerger B, Aerts I, Leblond P, Frappaz D, Gentet JC, Bracard S, André N. Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma. Cancer Chemother Pharmacol 2015; 76: 425-32.
3. Marrero L, Wyczechowska D, Musto AE, Wilk A, Vashistha H, Zapata A, Walker C, Velasco-Gonzalez C, Parsons C, Wieland S, Levitt D, Reiss K, Prakash O. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Neoplasia 2014; 16: 874-82.
4. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005; 25: 3825-31.
5. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13: 1238-41.
6. Sardi I. Morphine facilitates doxorubicin penetration in the central nervous system: a new prospect for therapy of brain tumors. J Neurooncol 2011; 104: 619-20.
7. Sardi I, la Marca G, Cardellicchio S, Giunti L, Malvagia S, Genitori L, Massimino M, de Martino M, Giovannini MG. Pharmacological modulation of blood-brain barrier increases permeability of doxorubicin into the rat brain. Am J Cancer Res 2013; 3: 424-32.
8. Bimonte S, Barbieri A, Palma G, Arra C. The role of morphine in animal models of human cancer: does morphine promote or inhibit the tumor growth? Biomed Res Int 2013; 2013: 258141.
9. Sharma HS, Ali SF. Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci 2006; 1074: 198-224.
10. Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol 2010; 11: 484-9.
11. Kast RE. Using blood brain barrier disruption by methamphetamine for drug delivery. J Neurooncol 2007; 85: 109-110.
12. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76: 22-76.
13. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27: 17-24.
14. Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol 2004; 67: 269-76.
15. Hellinger E, Veszelka S, Tóth AE, Walter F, Kittel A, Bakk ML, Tihanyi K, Háda V, Nakagawa S, Duy TD, Niwa M, Deli MA, Vastag M. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VBCaco- 2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 2012; 82: 340-51.
16. Solazzo M, Fantappiè O, D'Amico M, Sassoli C, Tani A, Cipriani G, Bogani C, Formigli L, Mazzanti R. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res 2009; 69: 7235-42.
17. Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ, Hulleman E. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One 2013; 8: e61512.
18. Caselli D, Tintori V, Messeri, A, Frenos, S, Bambi F, Aricò M. Respiratory depression and somnolence in children receiving dimethyl sulfoxide and morphine during hematopoietic stem cells transplantation. Haematologica 2009; 94: 152-3.
19. Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD, Gupta N. A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol 2010; 96: 151-9.
20. Kemper EM, Leenders W, Küsters B, Lyons S, Buckle T, Heerschap A, Boogerd W, Beijnen JH, van Tellingen O. Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies Eur J Cancer 2006; 42: 3294-303.
21. Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR. Antigen-specific activity of carcinoma- reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 1992; 52: 5693-700.
22. Kratz F, Fichtner I, Graeser R. Combination therapy with the albumin binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. Invest New Drugs 2012; 30: 1743-1749.
23. Kratz F, Azab S, Zeisig R, Fichtner I, Warnecke A. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin- binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model. Int J Pharm 2013; 441: 499-506.
24. Center for Drug Evaluation, Research (CDER). Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005.
25. Desai VG, Herman EH, Moland CL, Branham WS, Lewis SM, Davis KJ, George NI, Lee T, Kerr S, Fuscoe JC. Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model. Toxicol Appl Pharmacol 2013; 266: 109-21.
26. Cisternino S, Rousselle C, Dagenais C, Scherrmann JM. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in Pglycoprotein- deficient mice. Pharm Res 2001; 18: 183-90.